These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 10048755)

  • 21. Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.
    Mainwaring MG; Rimsza LM; Chen SF; Gomez SP; Weeks FW; Reddy V; Lynch J; May WS; Kahn S; Moreb J; Leather H; Braylan R; Rowe TC; Fieniewicz KJ; Wingard JR
    Leuk Lymphoma; 2002 May; 43(5):989-99. PubMed ID: 12148910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secondary leukemias induced by topoisomerase-targeted drugs.
    Felix CA
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):233-55. PubMed ID: 9748598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Downregulation of topoisomerase IIbeta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest.
    Chikamori K; Hill JE; Grabowski DR; Zarkhin E; Grozav AG; Vaziri SA; Wang J; Gudkov AV; Rybicki LR; Bukowski RM; Yen A; Tanimoto M; Ganapathi MK; Ganapathi R
    Leukemia; 2006 Oct; 20(10):1809-18. PubMed ID: 16932348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of diplochromosomes in mammalian cells by inhibitors of topoisomerase II.
    Sumner AT
    Chromosoma; 1998 Dec; 107(6-7):486-90. PubMed ID: 9914381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Micronuclei induction by carboplatin in human lymphocyte subpopulations.
    Slavutsky I; Campos E; Cid MG; Larripa I
    Anticancer Drugs; 1995 Dec; 6(6):758-62. PubMed ID: 8845488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficient induction of chromosome-type aberrations by topoisomerase II inhibitors closely associated with stabilization of the cleavable complex in cultured fibroblastic cells.
    Suzuki H; Ikeda T; Yamagishi T; Nakaike S; Nakane S; Ohsawa M
    Mutat Res; 1995 May; 328(2):151-61. PubMed ID: 7739599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of resistance to etoposide and adriamycin in a human glioma cell line treated with antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid of deoxyribonucleic acid topoisomerase II alpha.
    Kuriyama M; Tsutsui K; Tsutsui K; Ono Y; Tamiya T; Matsumoto K; Furuta T; Ohmoto T
    Neurol Med Chir (Tokyo); 1997 Sep; 37(9):655-61; discussion 661-2. PubMed ID: 9330528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
    Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
    Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytogenetic evidence that DNA topoisomerase II is not involved in radiation induced chromsome-type aberrations.
    Mosesso P; Pepe G; Ottavianelli A; Schinoppi A; Cinelli S
    Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():14-8. PubMed ID: 26520368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical resistance to topoisomerase-targeted drugs.
    Dingemans AM; Pinedo HM; Giaccone G
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):275-88. PubMed ID: 9748627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA.
    Gudkov AV; Zelnick CR; Kazarov AR; Thimmapaya R; Suttle DP; Beck WT; Roninson IB
    Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3231-5. PubMed ID: 8386368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
    Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
    Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells.
    Padget K; Stewart A; Charlton P; Tilby MJ; Austin CA
    Biochem Pharmacol; 2000 Sep; 60(6):817-21. PubMed ID: 10930536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topoisomerase activities in undifferentiated acute myeloblastic leukemias and monocytic differentiated leukemias.
    Gieseler F; Glasmacher A; Kämpfe D; Zernak C; Valsamas S; Kunze J; Clark M
    Recent Results Cancer Res; 1997; 143():321-7. PubMed ID: 8912429
    [No Abstract]   [Full Text] [Related]  

  • 35. Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.
    Errington F; Willmore E; Tilby MJ; Li L; Li G; Li W; Baguley BC; Austin CA
    Mol Pharmacol; 1999 Dec; 56(6):1309-16. PubMed ID: 10570059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells.
    López-Lázaro M; Willmore E; Austin CA
    Mutat Res; 2010 Feb; 696(1):41-7. PubMed ID: 20025993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
    Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
    Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
    Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paraoxon and glyphosate induce DNA double-strand breaks but are not type II topoisomerase poisons.
    Montero-Montoya R; Suárez-Larios K; Serrano-García L
    Mutat Res Genet Toxicol Environ Mutagen; 2023; 890():503657. PubMed ID: 37567644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
    Valkov NI; Sullivan DM
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):48-62. PubMed ID: 9408961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.